Esperion Expects Phase IIb Data By Year-End On Cholesterol Candidate
This article was originally published in The Pink Sheet Daily
Executive Summary
The recently public company completed Phase IIa studies for lead candidate ETC-1002 and intends to complete a pair of Phase IIb studies before year-end.